Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with medical professionals about care for people with non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease is now commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), although the terms are still often used interchangeably.

While the Department has not had any recent discussions with medical professionals about care for people with MASLD, NHS England has recently commenced a programme for the transformation of liver services. This programme is being led by the NHS England Hepatobiliary and Pancreas Clinical Reference Group (HPB CRG). HPB CRG is working with partners to co-produce resources to raise public knowledge and awareness of all forms of liver disease. In time, this may include incorporating liver health checks into the NHS Making Every Contact Count and NHS Health Checks initiatives.

The HPB CRG is also aiming to improve early diagnosis and intervention through developing evidence-based best-practice pathways for both primary care and referral to secondary care services. The HPB CRG is looking at access and equity of access to diagnostic tests across England and exploring the applicability of automated Fib4 tests and Intelligent Liver Function Testing, potentially utilising community diagnostic centres.

The British Society for Gastroenterology is currently updating its pathways and guidance for MASLD for both primary and secondary care, diagnostics, and treatment, which we anticipate will be published soon. There are also a number of ongoing National Institute for Health and Care Excellence assessments looking at new treatments for MASLD, including Resmetirom and Semaglutide. Outputs and recommendations are expected to be published in mid-2026.

Clinical teams also have access to NHS England’s Getting it Right First Time Advice and Guidance toolkit and templates for gastroenterology, which feature advice on managing abnormal liver function tests and MASLD. These templates enable general practitioners to seek timely advice from secondary care specialists, helping to reduce unnecessary delays.